Clinical Trial

HIV Antibody Increases Following Viral Rebound in People Receiving Antiretroviral Therapy

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to establish a proof-of-concept for whether rapid test can detect viral rebounds that occurred within a retrospective time window among PLHIV receiving ART in the United States and sub-Saharan Africa. The objective of this study is to assess whether HIV antibody levels rise following HIV viral rebound, and the sensitivity and specificity of antibody level increases for detecting HIV viral rebounds. The investigators will conduct a retrospective matched case-control study of individuals with or without suppressed viral load on antiretroviral therapy (ART). Biobanked specimens will be tested for antibody levels.
Trial Details
NCT Number NCT07665060
Lead Sponsor NYU Langone Health
Collaborators: Bill and Melinda Gates Foundation
Conditions HIV
Enrollment 6,100 participants
Start Date 2026-04-01
Primary Completion 2031-03-31 (estimated)
Study Completion 2031-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-24